TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial designed to determine the optimal dose and evaluate the effectiveness of TL938 and trastuzumab in treating patients with HER2+ colorectal cancer that has metastasized or recurred and is inoperable.